Event-Driven Stocks

Relypsa Inc

Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕

Signs1 good2 warning1 severedetails ↓

Financials

SEC XBRL · annual
 FY15FY14FY13
Revenue
Operating income−$29.3M−$15.7M−$70.9M
Net income−$29.7M−$16.1M−$73.8M
Total assets$278.3M$151.8M$106.0M
Total liabilities$93.5M$33.4M$31.2M
Equity$184.9M$118.5M$74.8M
EPS (diluted)
Shares out.41.3M35.0M29.7M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2015
Operating margin
Net margin
Return on equity
−16.0%
Return on assets
−10.7%
Return on capital (ROCE)
−14.0%
Liabilities / assets
33.6%
Debt / equity
0.51×
Book value / share
$4.48
Revenue growth (YoY)
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2015
Altman Z″ (distress)
0.11distress
Accruals / assets
28.9%high accruals
Piotroski F-Score
0/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
27
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

1 severe2 warning1 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
5 acquisitions7 disposalsnet 22,295 shares · last 12
InsiderDateTypeSharesPrice
Torley HelenDirectorSep 1, 2016U1,237$32.00
Spiegelman Daniel KDirectorSep 1, 2016U1,237$32.00
Schuetz Thomas J.DirectorSep 1, 2016U33,962$32.00
Mcgirr David W JDirectorSep 1, 2016U2,729$32.00
Hillan Kenneth J.DirectorSep 1, 2016U1,237$32.00
Hastings Paul JDirectorSep 1, 2016U2,495$32.00
Butler John P.DirectorSep 1, 2016U2,849$32.00
Stahl WilhelmOfficer — SVP, Chief Technology OfficerSep 1, 2016Grant2,917$0.00
Orwin John AOfficer — President &amp; CEOSep 1, 2016Grant11,250$0.00
Montgomery MonteOfficer — Chief Accounting OfficerSep 1, 2016Grant2,200$0.00
Krasnow Ronald A.Officer — See RemarksSep 1, 2016Grant2,917$0.00
Harrison Stephen DOfficer — SVP &amp; Chief Scientific OfficerSep 1, 2016Grant4,167$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.